Publications

Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.

Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Cárdenas MG, Yu W, Béguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest. 126(9):3351-62.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al..  2016.  Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.

Pyenson NC, Gayvert K, Varble A, Elemento O, Marraffini LA.  2017.  Broad Targeting Specificity during Bacterial Type III CRISPR-Cas Immunity Constrains Viral Escape.. Cell Host Microbe. 22(3):343-353.e3.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLeah B, A Van den Heuvel PJ, Lev A, Garnett MJ, McDermott U et al..  2017.  Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.. PLoS One. 12(8):e0180541.

Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM et al..  2017.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. Cancer Discov. 7(8):868-883.

Mendoza A, Fang V, Chen C, Serasinghe M, Verma A, Muller J, V Chaluvadi S, Dustin ML, Hla T, Elemento O et al..  2017.  Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells.. Nature. 546(7656):158-161.

Amengual JE, Prabhu SA, Lombardo M, Zullo K, Johannet PM, Gonzalez Y, Scotto L, Serrano XJirau, Wei Y, Duong J et al..  2017.  Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.. Clin Cancer Res. 23(12):3084-3096.

Kansler ER, Verma A, Langdon EM, Simon-Vermot T, Yin A, Lee W, Attiyeh M, Elemento O, White RM.  2017.  Melanoma genome evolution across species.. BMC Genomics. 18(1):136.

Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6

Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6

Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, Linder B, Pickering BF, Vasseur J-J, Chen Q et al..  2017.  Reversible methylation of mA in the 5' cap controls mRNA stability.. Nature. 541(7637):371-375.

Ge Y, Gomez NC, Adam RC, Nikolova M, Yang H, Verma A, Lu CPei-Ju, Polak L, Yuan S, Elemento O et al..  2017.  Stem Cell Lineage Infidelity Drives Wound Repair and Cancer.. Cell. 169(4):636-650.e14.

González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W et al..  2018.  Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.. Clin Cancer Res. 24(22):5697-5709.

Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang C-J et al..  2018.  Author Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.. Nat Genet. 50(5):764.

Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, Gray KD, Ullmann TM, Liang H, Moore MD et al..  2018.  CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules.. J Surg Oncol. 118(6):1042-1049.

Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK et al..  2018.  Chromosomal instability drives metastasis through a cytosolic DNA response.. Nature. 553(7689):467-472.

Faria M, Karami S, Granados-Principal S, Dey P, Verma A, Choi DS, Elemento O, Bawa-Khalfe T, Chang JC, Strom AM et al..  2018.  The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling.. Oncotarget. 9(15):12201-12211.

Liu Y, Choi DSoon, Sheng J, Ensor JE, Liang DHwang, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A et al..  2018.  HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.. Stem Cell Reports. 10(1):212-227.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.